Next Article in Journal
Serum Selenium Level and 10-Year Survival after Melanoma
Next Article in Special Issue
A Combined Spectroscopic and In Silico Approach to Evaluate the Interaction of Human Frataxin with Mitochondrial Superoxide Dismutase
Previous Article in Journal
Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer
Previous Article in Special Issue
New Insights of the NEET Protein CISD2 Reveals Distinct Features Compared to Its Close Mitochondrial Homolog mitoNEET
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 9
Issue 8
10.3390/biomedicines9080989
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Review of Multiple Mitochondrial Dysfunction Syndromes, Syndromes Associated with Defective Fe-S Protein Maturation

by
Elise Lebigot
1,*,
Manuel Schiff
2,3 and
Marie-Pierre Golinelli-Cohen
4,*
1
Bicêtre Hospital, AP-HP, Biochemistry Department, 94275 Le Kremlin-Bicêtre, France
2
Necker Hospital, AP-HP, Reference Center for Inborn Error of Metabolism and Filière G2M, Pediatrics Department, University of Paris, 75015 Paris, France
3
Inserm UMR_S1163, Institut Imagine, 75015 Paris, France
4
Institut de Chimie des Substances Naturelles, CNRS, UPR 2301, Université Paris-Saclay, 91198 Gif-Sur-Yvette, France
*
Authors to whom correspondence should be addressed.
Biomedicines 2021, 9(8), 989; https://doi.org/10.3390/biomedicines9080989
Submission received: 23 June 2021 / Revised: 3 August 2021 / Accepted: 6 August 2021 / Published: 10 August 2021
(This article belongs to the Special Issue Fe-S Proteins in Health and Disease)
Browse Figures
Versions Notes

Abstract

:
Mitochondrial proteins carrying iron-sulfur (Fe-S) clusters are involved in essential cellular pathways such as oxidative phosphorylation, lipoic acid synthesis, and iron metabolism. NFU1, BOLA3, IBA57, ISCA2, and ISCA1 are involved in the last steps of the maturation of mitochondrial [4Fe-4S]-containing proteins. Since 2011, mutations in their genes leading to five multiple mitochondrial dysfunction syndromes (MMDS types 1 to 5) were reported. The aim of this systematic review is to describe all reported MMDS-patients. Their clinical, biological, and radiological data and associated genotype will be compared to each other. Despite certain specific clinical elements such as pulmonary hypertension or dilated cardiomyopathy in MMDS type 1 or 2, respectively, nearly all of the patients with MMDS presented with severe and early onset leukoencephalopathy. Diagnosis could be suggested by high lactate, pyruvate, and glycine levels in body fluids. Genetic analysis including large gene panels (Next Generation Sequencing) or whole exome sequencing is needed to confirm diagnosis.

1. Introduction

Conserved across all kingdoms of life, iron-sulfur (Fe-S) clusters are ancient prosthetic groups. They are found in a variety of proteins involved in diverse essential cellular pathways such as the Krebs cycle, the mitochondrial respiratory chain (RC), or in DNA replication and repair [1]. The mitochondrion plays an essential role in the biogenesis of Fe-S. However, the functioning of this essential organelle for cellular energy production is itself dependent on Fe-S cluster-containing proteins. In mammals, Fe-S protein maturation occurs via three distinct and organized biosynthetic pathways. Fe-S cluster biosynthesis always begins in the mitochondrion with de novo [2Fe-2S] cluster formation on the cluster scaffold protein ISCU. The cluster is then transferred to the cluster delivery protein, Glutaredoxin 5 or GLRX5. Maturation of the mitochondrial [2Fe-2S]-containing proteins can directly proceed from GLRX5, while the maturation of the [4Fe-4S]-containing proteins requires supplementary steps with the biosynthesis of the [4Fe-4S] cluster and its delivery to mitochondrial [4Fe-4S] proteins [2,3]. These last steps involve six proteins, namely NUBPL (formerly named IND1), NFU1, BOLA3, IBA57, ISCA2, and ISCA1, whose functions are poorly known and are currently the subject of intense research [4,5] (Figure 1).
First identified in 2011, deleterious variants in the genes encoding for five of these proteins, NFU1, BOLA3, IBA57, ISCA2, and ISCA1, lead to a disease named multiple mitochondrial dysfunction syndrome (MMDS) types 1 to 5, respectively, with symptoms indicative of a general decreased energy metabolism and mitochondrial respiration failure. To date, less than 150 patients with MMDS were reported worldwide. The signs and symptoms of these severe conditions begin early in life, and affected individuals usually do not live past infancy. The most affected tissues in these syndromes are those requiring a lot of energy such as heart, brain, and muscle. Pathophysiology is related to a specific impairment of the maturation of downstream mitochondrial [4Fe-4S]-cluster-containing proteins, which results in a deficiency of mitochondrial respiratory complexes and the impaired function of lipoic-acid-dependent enzymes.
The present review will focus on the MMDS. The methodology we have adopted was based on Pubmed searches using “multiple mitochondrial dysfunction syndrome”, “NFU1”, “BOLA3”, “IBA57”, “ISCA2”, and “ISCA1” as keywords. We included all publications describing a new patient with confirmed genetic analyses.

2. Fe-S Proteins: Essential Proteins with Elaborated Maturation Pathways

Since their discovery in bacteria in the 1960s, Fe-S proteins were found to execute a large range of functions in prokaryotic archaea and bacteria as well as in eukaryotic fungi, plants, and animals. They are among the most ubiquitous and versatile metal-containing prosthetic centers and sustain fundamental processes including mitochondrial respiration, the Krebs cycle, DNA metabolism, and cellular iron homeostasis [1,6,7,8,9]. We will start this review by highlighting the essential roles of Fe-S proteins in human cells and their biogenesis pathways.
Fe-S clusters are inorganic prosthetic groups composed of one or more iron ions that are partially or completely coordinated by sulfur atoms. In many proteins, they are associated with other types of cofactors such as organic groups (e.g., flavin) or other metal atoms. Fe-S clusters found in proteins have different atom compositions, cluster structures, and core oxidation states. The most common configurations are the [2Fe-2S], and the [4Fe-4S] core units. The tetrahedral coordination of each iron site is performed by cluster inorganic sulfides (S2−) and protein-based ligands, which are generally thiolate groups provided by cysteine residues [1,6,7].
Fe-S clusters are typically redox active. In other words, they can be found in different oxidation states. Thus, each iron ion of the cluster can be either in the oxidized state, Fe(III) (ferric ion), or in the reduced state, Fe(II) (ferrous ion). Fe-S proteins use this property to mediate electron transport (coupled or not to proton transfer) as is the case in the respiratory chain. However, Fe-S clusters can also constitute the active site of a wide range of enzymes including in the [4Fe-4S]-containing aconitase [10] and the members of the fast-growing and diverse radical-SAM (S-adenosyl-L-methionine) superfamily [11]. Fe-S proteins have many other functions such as Fe-S cluster biogenesis (ISCU, ISCA…) or repair (mitoNEET) [12], ribosome synthesis (ABCE1) [13], DNA polymerization and repair [14], sulfur donation (biotin synthase) [15], and the ability to sense different types of environmental stimuli and stress [16,17]. Thus, Fe-S clusters are essential cofactors for various proteins involved in key cellular functions.
The first studies on the biogenesis of Fe-S clusters were performed on bacteria [18] and homologous proteins were then identified in yeast and humans [19,20]. While in vitro chemical reconstitution of Fe-S clusters can occur spontaneously in the presence of proteins that are able to coordinate an Fe-S cluster, it requires several complex protein machineries in vivo to avoid the toxic effects of free iron and inorganic sulfur. In humans, the maturation of Fe-S proteins is a very complex process involving more than 25 proteins, and there are still many grey areas regarding how these proteins cooperate with each other. We will not attempt to describe the entire biogenesis of Fe-S clusters in detail here (see recent reviews including [2,3,5]), but we will give the reader an overview of this process and of the roles of the proteins involved in MMDS.
There are three machineries that have been clearly identified. The mitochondrial Iron-Sulfur Cluster (ISC) assembly machinery is devoted to the formation of the initial Fe-S cluster and to the maturation of mitochondrial Fe-S proteins. An ATP-binding cassette (ABC)-type export machinery brings an unknown sulfur-containing compound X-S, which could also contain iron, out of the mitochondrion to the cytosol [21,22]. Finally, the Cytosolic Iron-sulfur Assembly (CIA) machinery is devoted to the maturation of non-mitochondrial Fe-S proteins. The maturation of all of the mammalian Fe-S proteins always starts in the mitochondrion regardless of the subcellular localization of the protein to be matured.
The mitochondrial process can itself be subdivided in three main steps. First, an initial [2Fe-2S] 2+ cluster is built de novo on the scaffold protein ISCU by assembling two Fe2+ ions imported into the mitochondrion by the inner mitochondrial membrane transporters, called mitoferrins [23], and two sulfide ions produced from the desulfuration of the cysteines by the NFS1-ISD11-ACP complex [24,25,26]. This first step also requires electrons provided by the ferredoxin FDX2 [27,28,29] and is regulated by frataxin according to a still debated mechanism [30,31]. The newly made [2Fe-2S]2+ is then released from ISCU and transferred to the monothiol GLRX5 with the help of the HSPA9/HSC20 chaperone pair. However, recent studies have proposed that ISCU could transfer its cluster to not only GLRX5 but also to specific mitochondrial [2Fe-2S] proteins containing conserved LYR motifs [32,33]. Finally, the GLRX5-bound cluster can be directly inserted into mitochondrial [2Fe-2S]-containing proteins that are then exported out of the mitochondrion or are converted to a [4Fe-4S] cluster.
The late-acting steps of the mitochondrial pathway responsible for the maturation of mitochondrial [4Fe-4S] clusters are still elusive. Proteins mutated in MMDS, namely ISCA1, ISCA2, IBA57, NFU1, and BOLA3, are all involved with NUBPL in these last steps devoted to the maturation of mitochondrial [4Fe-4S]-containing proteins. NUBPL would be exclusively involved in the maturation of [4Fe-4S]-containing proteins of complex I of the RC [34,35]. However, the exact functions of the five other proteins and how they cooperate are still poorly characterized. On the heterocomplex ISCA1-ISCA2, the reductive fusion of two GLRX5-derived [2Fe-2S]2+ clusters leading to the formation of [4Fe-4S]2+ after the addition of two electrons provided by FDX2 [36]. Some studies involve IBA57 in this step [36,37,38]; however, its implication in the formation of the [4Fe-4S] cluster is still debated [39,40], with some other studies involving IBA57 in the maturation of specific mitochondrial [2Fe-2S] proteins [41]. This [4Fe-4S] cluster can be directly inserted in several mitochondrial [4Fe-4S]-containing proteins, such as the Krebs enzyme aconitase. However, most of them, including the subunits of the respiratory complexes I and II and the lipoic acid synthase (LIAS) involved in the critical modifications of the pyruvate dehydrogenase (PDH) and of the alpha-ketoglutarate dehydrogenase (αKGDH) complexes, require dedicated late-acting ISC targeting factors including NFU1 and BOLA3 for their maturation [42,43,44,45,46]. Deficiency in one of these proteins that is caused by deleterious variants in the corresponding gene leading to multiple mitochondrial [4Fe-4S] protein dysfunction, except for NUBPL, whose deficiency is limited to complex I impairment.

3. MMDS Type 1 (MMDS1), Mutation in NFU1

Since the first patients described in 2011 [47,48], more than 35 patients with MMDS1 (OMIM#605711) have been reported from all continents (Table 1). This disorder is caused by biallelic pathogenic variants in the NFU1 gene. Severe encephalopathy was the clinical feature with early onset (less than one year of age) in the initial patients. Their atypical metabolic profiles revealed decreased activity of multiple mitochondrial proteins (PDH, Glycine Cleavage System (GCS), and respiratory chain complexes (RCC)) leading to the first MMDS description.
Supplementary analysis on tissues from patients with MMDS1 found that PDH and GCS impairment was secondary to lipoic acid synthesis disruption. These biochemical characteristics suggested that human NFU1 was involved in the maturation of Fe-S cluster-containing proteins, as is the case in its orthologue protein Nfu in plants [61] and in bacteria [62]. Clinical features showed unspecific signs of energetic metabolism disease (axial hypotonia, apnea, myoclonus or seizures, developmental delay) with dramatic evolution. Pulmonary arterial hypertension (PAHT) was reported in several patients and was then linked to a specific genetic variant, which is also the the most frequent, the Gly208Cys, at either the heterozygous or the homozygous state. This variant modifies the native CysXXCys scheme essential for Fe-S carriage by the NFU1 protein to CysXCysXXCys [63]. In vitro analysis revealed functional impairment of NFU1 Gly208Cys compared to the native protein. The consequence would be an increased retention of the Fe-S cluster by the mutated protein, inhibiting its transfer to acceptor proteins [48,63]. Recently, a study in rats showed that PAHT as well as mitochondrial dysfunction (complexes I and II, and PDH activities) were clearly linked to this variant in NFU1 [64] with a more drastic effect in homozygous female rats. However, this dimorphism gender was not evident in patients with MMDS1. Hypertrophy in the cardiac left ventricle was not detected in animals carrying this variant. Biochemical analysis showed atypical results for several NFU1 patients compared to other subjects. PDH and RCC activities were indeed not decreased in one patient carrying variant c.545 + 5G > A [54]. Lipoic acid synthesis was not impaired in the fibroblasts of a patient carrying the variant c.179T > C at the homozygous state [50]. These two genotypes could be associated to specific biochemical phenotypes. Among the 13 other variants identified in patients with MMDS1 (Table 1, Figure 2), the second most frequent variant was the missense variant Gly189Arg, which was carried by 5 patients. Some authors have suggested that this variant could be associated with a milder progressive disease [53]. One patient, who was carrying it at the homozygous state, had a later disease onset than usually described and was still alive at 41 months [58]. An Italian patient, a composite heterozygote carrier of the Gly189Arg and Pro49Leufs*8 variants, was the only one to be alive as an adult [52]. His clinical phenotype is clearly atypical compared to that of other patients, as the patient experienced a neurological regression episode at late onset (18 months) with partial recovery. No other decompensation episodes were noticed, and first clinical and biological investigations were only performed at 18 years of age. The predominant clinical feature at adult stage was described as peripheral neuropathy mimicking PDH deficiency, the activity of which was deeply decreased in the fibroblasts. Other classical biochemical findings in NFU1 patients (high glycine levels, decreased RC activities) were also present. Indeed, except for these two patients, all of the others died in the first three years of life regardless of the genotype. Neither treatment based on lipoic acid or other vitamin cocktails nor a ketogenic diet was efficient [49]. The authors suggested epigenetic factors as possible modulator effects and as an explanation for the exceptional life span of the Italian patient [52]. Metabolomic investigations in different tissues or body fluids could be helpful to provide further compensatory pathways involved in several tissues of this patient.

4. MMDS Type 2, Mutations in BOLA3

Variants in BOLA3 cause MMDS type 2 (OMIM#614299), which can be described as a severe mitochondrial disease leading to early death in almost all patients. The first patient was reported 10 years ago [47] and the clinical phenotype showed severe encephalopathy with respiratory distress, seizures, failure to thrive, and dilated cardiomyopathy. Biochemical findings in this patient resembled those of MMDS1, which included increased glycine levels in body fluids and decreased activity of complexes I and II of the RC and PDH. The lipoylation of mitochondrial proteins was also impaired. Since 2011, at least fifteen patients from worldwide origins were reported (Table 2).
The clinical phenotype was similar to that of the first MMDS2 patient, and cardiomyopathy was mentioned in half of the patients. Hypertrophic and dilated cardiomyopathies were described. Psychomotor regression was frequently the first symptom reported and began in the first year of life in most of the patients. Optic atrophy or nystagmus were reported in three patients [66,70]. In one patient, acute right hemiparesis revealed the disease at 18 months of age [72].
Brain imaging findings showed bilateral periventricular and deep white matter until spinal cord lesions formed in most cases, without further specification. Demyelination was also frequently observed. Biochemical analyses were performed using different tissues of several patients. As expected, high levels of glycine and lactate in body fluids and decreased PDH and complex I and II activity were found in most patients. However, the activities of these complexes were normal for a few patients. Thus, MMDS2 could not be ruled out for a patient with normal RCC activity.
Among the 18 reported patients from 14 families worldwide, only 8 variants were identified (Figure 3).
The three types are either stop, frameshift mutation, or deletion in the second exon, while the missense mutations are localized in exons 3 and 4. The mutations Cys59Tyr and His96Arg affect highly conserved residues that are crucial for protein functionality [74]. Other missense variants modified amino acids involved in the β-strands. His96Arg was only identified in the Japanese patients. It is noteworthy that both patients carrying the homozygous variant Arg99Trp presented a milder phenotype than the others [69]. Of those two patients, one was the only patient still alive at 12 years of age, and no cardiomyopathy was mentioned in his clinical description. The second one could have benefitted from immunomodulation treatment (methylprednisolone), which could have led to partial improvement without long-term follow-up for this patient. The other reported patients were often treated with classical vitamin cocktails without clear effectiveness [75]. A milder clinical phenotype with longer survival was observed in patients carrying the Cys59Tyr variant, which is also [72] due to the partial dysfunction of mutated protein [76].
BOLA3 is indeed involved in the delivery of an [4Fe-4S] cluster from GLRX5 to recipient mitochondrial Fe-S proteins with the help of NFU1. Both NFU1 and BOLA3 deficiencies lead to similar clinical phenotypes, including severe encephalopathy and cardiac impairment. In MMDS1, pulmonary hypertension is clearly related to one pathogenic variant (Gly208Cys) without hypertrophic cardiomyopathy for most patients. However, to date, no animal experiments have been performed to improve knowledge regarding the cardiomyopathy detected in MMDS2 patients. Recently, in vitro assessment of BOLA3 knockdown in human pulmonary artery endothelial cells confirmed that BOLA3 regulates glycolysis, mitochondrial Fe-S protein maturation, and mitochondrial respiration activity [77]. In this human cellular model, BOLA3 deficiency leads to increased endothelial vasoconstriction, while in mice cells, it causes histological modifications typical of those found in pulmonary hypertension.

5. MMDS Type 3 (MMDS3), Mutations in IBA57

Biallelic pathogenic variants in IBA57 leading to MMDS type 3 were first reported in a family involving two siblings [78]. They presented with antenatal signs of polyhydramnios and microcephaly. Biochemical studies in fibroblasts and muscle identified decreased activity in the RC complexes I, II, and IV and in the lipoylated proteins. Both patients died in the neonatal period. Since this first publication, 25 other families with MMDS3 involving 57 patients have been reported without additional patients with antenatal signs (Table 3).
Eye findings such as optic atrophy and/or nystagmus or abnormal vision evoked potentials were present in almost half of the patients (28/59). Psychomotor regression with progressive spasticity potentially leading to quadriparesis was the most frequent initial clinical feature with variable onset age. However, more than 20 patients were still alive after 5 years of age. For one patient, treatment with riboflavin, coenzyme Q10, and baclofene led to a slow clinical recovery, and seizures were efficiently treated by levetiracetam [75]. Brain imaging of the described patients revealed very frequent cavitating leukoencephalopathy (Table 3). Interestingly, in a cohort of 37 patients with this imaging feature, 46% were carrying IBA57 variants [84]. Biochemical findings were hyperlactatemia in most of the patients. A high level of blood glycine was found in only a few patients. The activity of the RC complexes I, II, and IV were often impaired in patients who were also associated with a low level of lipoylated proteins in the fibroblasts. Nevertheless, RC was not systematically impaired in the fibroblasts [75,82]. To date, 34 pathogenic variants in IBA57 have been identified without frequent variant nor evident genotype- phenotype correlation (Figure 4). However, the variant c.678A > G identified in 12 related patients of Palestinian origin could be associated with the SPOAN-like phenotype (spastic paraplegia, optic atrophy and peripheral neuropathy) [79]. All of these patients survived until adulthood. Biochemical findings in the fibroblasts showed residual lipoylation of mitochondrial proteins suggesting the residual efficiency of mutated IBA57 in the Fe-S protein maturation pathway resulting in a milder clinical phenotype.

6. MMDS Type 4, Mutations in ISCA2

In 2015, seven patients from six families exhibiting severe neurodevelopmental regression, spasticity, and optic atrophy were reported [86,87]. Molecular studies revealed a homozygous variant in ISCA2 for each patient, the Gly77Ser variant, leading to the description of the first patients with MMDS 4 (OMIM#616370). To date 24 patients have been reported, including 19 Saudi patients carrying the same variant [88,89,90] (Table 4).
Clinical and neuroimaging findings were quite similar between all of the described patients. Initial psychomotor development was normal and clinical status was deteriorated during the first year of life leading to spasticity and visual impairment (nystagmus and/or optic atrophy), as is the case for other mitochondrial disorders. Lesions in cerebral and cerebellar white matter and the spinal cord were indeed quite constantly present and may suggest a leukoencephalopathy with brainstem and spinal cord involvement and high brain lactate (LBSL) caused by the DARS2 mutation [91]. Death could occur in the neonatal period or in the first years of life (Table 4). Most of the surviving adolescent patients exhibited an extremely severe encephalopathy. To date, no patient has lived to adulthood.
Biochemical analyses including an RC functional study showed that all complexes might be affected [93] but the activity of complexes III and V were rarely decreased in the tissues of patients with ISCA2 deficiency [50,89]. Lipoylated proteins (PDH, KGDH) were also decreased in the fibroblasts of patients, in accordance with the involvement of ISCA2 in the maturation of mitochondrial [4Fe-4S] proteins [94]. Interestingly, mitochondrial morphology with mitochondrial network disruption was abnormal in the fibroblasts of ISCA2 deficient patients [89]. Mitochondrial DNA depletion was also present in several studies, including in fibroblasts from Saudi ISCA2 deficient patients [86,89]. This variant seemed to be a founder mutation in Saudi families, while in five other patients from different countries, seven sporadic variants were identified. These seven variants affect all regions of the ISCA2 protein (Figure 5).

7. MMDS Type 5, Mutations in ISCA1

Pathogenic variants in ISCA1 lead to MMDS type 5, the most recently described MMDS [95]. The first four reported cases exhibited severe neonatal encephalopathy. Among the seven described cases from five families, five were from Indian families [95,96], while the other patients were of Italian [97] and Egyptian [98] origins. All of the Indian patients carried the same homozygous variant Gln87Lys, whereas the homozygous variants Val10Gly and Tyr101Cys were identified in the Italian and Egyptian patients, respectively (Table 5). Biochemical investigations showed expected hyperlactatemia and elevated urinary glycine level (one case). Elevated creatine phosphokinase (CPK) was reported in one of the two tested Indian patients. Mitochondrial protein studies were performed in tissues of patients carrying the Val10Gly and Tyr101Cys variants. The lipoylation of the mitochondrial proteins was impaired. The functionality of the RCC was differently affected depending on the analyzed tissues, but the dysfunction of complexes II and IV was always observed [97,98]. These findings suggest that ISCA1 impairment does not affect the maturation of [2Fe-2S] proteins (including the Rieske protein of complex III but only that of the mitochondrial [4Fe-4S] proteins [97].
From all the seven ISCA1 cases, two clinical presentations would be summarized as (i) severe early encephalopathy with major psychomotor retardation and few or no achieved milestones leading to early death or (ii) moderate encephalopathy. The first category is linked to Indian patient genotype while the second category is linked to the others. Spasticity (n = 7/7), nystagmus (n = 2/7), and seizures (n = 2/7) were the other neurological symptoms. However, there was an early mortality for most of the patients: among seven cases, five of them died between 11 months and 11 years old.
Brain magnetic resonance imaging (MRI) showed frequent abnormalities such as ventriculomegaly, but other imaging data were associated with different genotypes. Cerebral and cerebellar white matter leukodystrophy and pachygyria were present in patients carrying the Gln87Lys variant, while thin corpus callosum associated with vacuolating leukodystrophy were described in other patients. As expected, the lactate peak in brain magnetic resonance (MR) spectroscopy was also present in the majority of affected individuals.
To date, the seven reported patients with MMDS type 5 presented some similar clinical features as individuals with mitochondrial cytopathy or PDH deficiency without distinctive imaging or a biochemical phenotype compared to other MMDS.

8. Conclusions

Since the development of next generation sequencing and whole exome (or genome) sequencing in the year 2010, pathogenic variants in genes encoding for the proteins involved in the late steps of the mitochondrial Fe-S protein maturation pathway were identified in diseased patients. They exhibited severe or fatal early onset encephalopathy with multiple biochemical abnormalities (RCC, PDH, Krebs enzymes impairment) and secondary to mitochondrial [4Fe-4S] proteins maturation disorder. Despite classification of MMDS into five different categories according to the mutated gene, clinical symptoms, brain imaging, and biochemical components, findings are quite homogeneous, resembling other severe mitochondrial leukoencephalopathies such as LBSL, for instance. A lactate peak on MR spectroscopy was also often observed as in classic mitochondriopathies. The ophthalmologic manifestations usually present in patients with other mitochondrial diseases [99] and have frequently been reported in MMDS types 3, 4, and 5; rarely in MMDS type 2; and never in type 1. The reason why these manifestations are inconstant in patients with MMDS remains unknown, but it suggests that an ophthalmological examination is needed for all patients with established MMDS. Associated with encephalopathy, cardiac impairment such as PAHT (isolated or not) and dilated cardiomyopathy could suggest MMDS type 1 or type 2, respectively. With respect to specific biochemical findings, the accumulation of glycine and lactate in body fluids was frequently, albeit not always, noted as were decreased RCC activities.

Author Contributions

Conceptualization and methodology, E.L. and M.-P.G.-C.; validation, E.L., M.S. and M.-P.G.-C.; writing—original draft preparation, E.L. and M.-P.G.-C.; writing—review and editing, E.L., M.S. and M.-P.G.-C.; visualization, E.L., M.S. and M.-P.G.-C.; supervision, M.-P.G.-C.; project administration, E.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

MPGC warmly acknowledges the networking support from the EU COST Action FeSBioNet (CA15133).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Johnson, D.C.; Dean, D.R.; Smith, A.D.; Johnson, M.K. Structure, Function, and Formation of Biological Iron-Sulfur Clusters. Annu. Rev. Biochem. 2005, 74, 247–281. [Google Scholar] [CrossRef]
  2. Rouault, T.A.; Maio, N. Biogenesis and Functions of Mammalian Iron-Sulfur Proteins in the Regulation of Iron Homeostasis and Pivotal Metabolic Pathways. J. Biol. Chem. 2017, 292, 12744–12753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Braymer, J.J.; Freibert, S.A.; Rakwalska-Bange, M.; Lill, R. Mechanistic Concepts of Iron-Sulfur Protein Biogenesis in Biology. Biochim. Biophys. Acta Mol. Cell Res. 2021, 1868, 118863. [Google Scholar] [CrossRef]
  4. Wachnowsky, C.; Fidai, I.; Cowan, J.A. Iron-Sulfur Cluster Biosynthesis and Trafficking-Impact on Human Disease Conditions. Metallomics 2018, 10, 9–29. [Google Scholar] [CrossRef] [PubMed]
  5. Ciofi-Baffoni, S.; Nasta, V.; Banci, L. Protein Networks in the Maturation of Human Iron-Sulfur Proteins. Metallomics 2018, 10, 49–72. [Google Scholar] [CrossRef]
  6. Beinert, H. Iron-Sulfur Proteins: Ancient Structures, Still Full of Surprises. J. Biol. Inorg. Chem. 2000, 5, 2–15. [Google Scholar] [CrossRef] [PubMed]
  7. Meyer, J. Iron-Sulfur Protein Folds, Iron-Sulfur Chemistry, and Evolution. J. Biol. Inorg. Chem. 2008, 13, 157–170. [Google Scholar] [CrossRef]
  8. Pain, D.; Dancis, A.; Bielas, J.; Suzuki, C. Roles of Fe–S Proteins: From Cofactor Synthesis to Iron Homeostasis to Protein Synthesis This Review Comes from a Themed Issue on Molecular and Genetic Bases of Disease. Curr. Opin. Genet. Dev. 2016, 38, 45–51. [Google Scholar] [CrossRef] [Green Version]
  9. Rouault, T.A. The Indispensable Role of Mammalian Iron Sulfur Proteins in Function and Regulation of Multiple Diverse Metabolic Pathways. Biometals 2019, 32, 343–353. [Google Scholar] [CrossRef] [Green Version]
  10. Lauble, H.; Stout, C.D. Steric and Conformational Features of the Aconitase Mechanism. Proteins 1995, 22, 1–11. [Google Scholar] [CrossRef]
  11. Broderick, W.E.; Broderick, J.B. Radical SAM Enzymes: Surprises along the Path to Understanding Mechanism. J. Biol. Inorg. Chem. 2019, 24, 769–776. [Google Scholar] [CrossRef] [PubMed]
  12. Ferecatu, I.; Gonçalves, S.; Golinelli-Cohen, M.-P.; Clémancey, M.; Martelli, A.; Riquier, S.; Guittet, E.; Latour, J.-M.; Puccio, H.; Drapier, J.-C.; et al. The Diabetes Drug Target MitoNEET Governs a Novel Trafficking Pathway to Rebuild an Fe-S Cluster into Cytosolic Aconitase/Iron Regulatory Protein 1. J. Biol. Chem. 2014, 289, 28070–28086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kispal, G.; Sipos, K.; Lange, H.; Fekete, Z.; Bedekovics, T.; Janáky, T.; Bassler, J.; Aguilar Netz, D.J.; Balk, J.; Rotte, C.; et al. Biogenesis of Cytosolic Ribosomes Requires the Essential Iron-Sulphur Protein Rli1p and Mitochondria. EMBO J. 2005, 24, 589–598. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Fuss, J.O.; Tsai, C.L.; Ishida, J.P.; Tainer, J.A. Emerging Critical Roles of Fe-S Clusters in DNA Replication and Repair. Biochim. Biophys. Acta 2015, 1853, 1253–1271. [Google Scholar] [CrossRef] [Green Version]
  15. Fugate, C.J.; Jarrett, J.T. Biotin Synthase: Insights into Radical-Mediated Carbon-Sulfur Bond Formation. Biochim. Biophys. Acta 2009, 1824, 1213–1222. [Google Scholar] [CrossRef]
  16. Crack, J.C.; Green, J.; Thomson, A.J.; le Brun, N.E. Iron-Sulfur Clusters as Biological Sensors: The Chemistry of Reactions with Molecular Oxygen and Nitric Oxide. Acc. Chem. Res. 2014, 47, 3196–3205. [Google Scholar] [CrossRef]
  17. Golinelli-Cohen, M.-P.; Bouton, C. Fe-S Proteins Acting as Redox Switch: New Key Actors of Cellular Adaptive Responses. Curr. Chem. Biol. 2017, 11, 1–19. [Google Scholar] [CrossRef]
  18. Zheng, L.; White, R.H.; Cash, V.L.; Jack, R.F.; Dean, D.R. Cysteine Desulfurase Activity Indicates a Role for NIFS in Metallocluster Biosynthesis. Proc. Natl. Acad. Sci. USA 1993, 90, 2754–2758. [Google Scholar] [CrossRef] [Green Version]
  19. Land, T.; Rouault, T.A. Targeting of a Human Iron-Sulfur Cluster Assembly Enzyme, Nifs, to Different Subcellular Compartments Is Regulated through Alternative AUG Utilization. Mol. Cell 1998, 2, 807–815. [Google Scholar] [CrossRef]
  20. Kispal, G.; Csere, P.; Prohl, C.; Lill, R. The Mitochondrial Proteins Atm1p and Nfs1p Are Essential for Biogenesis of Cytosolic Fe/S Proteins. EMBO J 1999, 18, 3981–3989. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Li, J.; Cowan, J.A. Glutathione-Coordinated [2Fe–2S] Cluster: A Viable Physiological Substrate for Mitochondrial ABCB7 Transport. Chem. Commun. 2015, 51, 2253–2255. [Google Scholar] [CrossRef]
  22. Srinivasan, V.; Pierik, A.J.; Lill, R. Crystal Structures of Nucleotide-Free and Glutathione-Bound Mitochondrial ABC Transporter Atm1. Science 2014, 343, 1137–1140. [Google Scholar] [CrossRef]
  23. Paradkar, P.N.; Zumbrennen, K.B.; Paw, B.H.; Ward, D.M.; Kaplan, J. Regulation of Mitochondrial Iron Import through Differential Turnover of Mitoferrin 1 and Mitoferrin 2. Mol. Cell. Biol. 2009, 29, 1007–1016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Adam, A.C.; Bornhövd, C.; Prokisch, H.; Neupert, W.; Hell, K. The Nfs1 Interacting Protein Isd11 Has an Essential Role in Fe/S Cluster Biogenesis in Mitochondria. EMBO J. 2006, 25, 174–183. [Google Scholar] [CrossRef] [Green Version]
  25. Wiedemann, N.; Urzica, E.; Guiard, B.; Müller, H.; Lohaus, C.; Meyer, H.E.; Ryan, M.T.; Meisinger, C.; Mühlenhoff, U.; Lill, R.; et al. Essential Role of Isd11 in Mitochondrial Iron-Sulfur Cluster Synthesis on Isu Scaffold Proteins. EMBO J. 2006, 25, 184–195. [Google Scholar] [CrossRef]
  26. Boniecki, M.T.; Freibert, S.A.; Mühlenhoff, U.; Lill, R.; Cygler, M. Structure and Functional Dynamics of the Mitochondrial Fe/S Cluster Synthesis Complex. Nat. Commun. 2017, 8, 1287. [Google Scholar] [CrossRef] [Green Version]
  27. Sheftel, A.D.; Stehling, O.; Pierik, A.J.; Elsasser, H.-P.; Muhlenhoff, U.; Webert, H.; Hobler, A.; Hannemann, F.; Bernhardt, R.; Lill, R. Humans Possess Two Mitochondrial Ferredoxins, Fdx1 and Fdx2, with Distinct Roles in Steroidogenesis, Heme, and Fe/S Cluster Biosynthesis. Proc. Natl. Acad. Sci. USA 2010, 107, 11775–11780. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Webert, H.; Freibert, S.A.; Gallo, A.; Heidenreich, T.; Linne, U.; Amlacher, S.; Hurt, E.; Mühlenhoff, U.; Banci, L.; Lill, R. Functional Reconstitution of Mitochondrial Fe/S Cluster Synthesis on Isu1 Reveals the Involvement of Ferredoxin. Nat. Commun. 2014, 5, 5013. [Google Scholar] [CrossRef] [Green Version]
  29. Cai, K.; Tonelli, M.; Frederick, R.O.; Markley, J.L. Human Mitochondrial Ferredoxin 1 (FDX1) and Ferredoxin 2 (FDX2) Both Bind Cysteine Desulfurase and Donate Electrons for Iron-Sulfur Cluster Biosynthesis. Biochemistry 2017, 56, 487–499. [Google Scholar] [CrossRef] [PubMed]
  30. Tsai, C.L.; Barondeau, D.P. Human Frataxin Is an Allosteric Switch That Activates the Fe-S Cluster Biosynthetic Complex. Biochemistry 2010, 49, 9132–9139. [Google Scholar] [CrossRef]
  31. Parent, A.; Elduque, X.; Cornu, D.; Belot, L.; le Caer, J.P.; Grandas, A.; Toledano, M.B.; D’Autreaux, B. Mammalian Frataxin Directly Enhances Sulfur Transfer of NFS1 Persulfide to Both ISCU and Free Thiols. Nat. Commun. 2015, 6, 5686. [Google Scholar] [CrossRef] [Green Version]
  32. Maio, N.; Ghezzi, D.; Verrigni, D.; Rizza, T.; Bertini, E.; Martinelli, D.; Zeviani, M.; Singh, A.; Carrozzo, R.; Rouault, T.A. Disease-Causing SDHAF1 Mutations Impair Transfer of Fe-S Clusters to SDHB. Cell Metab. 2016, 23, 292–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Maio, N.; Singh, A.; Uhrigshardt, H.; Saxena, N.; Tong, W.H.; Rouault, T.A. Cochaperone Binding to LYR Motifs Confers Specificity of Iron Sulfur Cluster Delivery. Cell Metab. 2014, 19, 445–457. [Google Scholar] [CrossRef] [Green Version]
  34. Bych, K.; Kerscher, S.; Netz, D.J.A.; Pierik, A.J.; Zwicker, K.; Huynen, M.A.; Lill, R.; Brandt, U.; Balk, J. The Iron-Sulphur Protein Ind1 Is Required for Effective Complex I Assembly. EMBO J. 2008, 27, 1736–1746. [Google Scholar] [CrossRef] [Green Version]
  35. Sheftel, A.D.; Stehling, O.; Pierik, A.J.; Netz, D.J.A.; Kerscher, S.; Elsässer, H.-P.; Wittig, I.; Balk, J.; Brandt, U.; Lill, R. Human Ind1, an Iron-Sulfur Cluster Assembly Factor for Respiratory Complex I. Mol. Cell. Biol. 2009, 29, 6059–6073. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Weiler, B.D.; Brück, M.C.; Kothe, I.; Bill, E.; Lill, R.; Mühlenhoff, U. Mitochondrial [4Fe-4S] Protein Assembly Involves Reductive [2Fe-2S] Cluster Fusion on ISCA1-ISCA2 by Electron Flow from Ferredoxin FDX2. Proc. Natl. Acad. Sci. USA 2020, 117, 20555–20565. [Google Scholar] [CrossRef] [PubMed]
  37. Sheftel, A.D.; Wilbrecht, C.; Stehling, O.; Niggemeyer, B.; Elsasser, H.P.; Muhlenhoff, U.; Lill, R. The Human Mitochondrial ISCA1, ISCA2, and IBA57 Proteins Are Required for [4Fe-4S] Protein Maturation. Mol. Biol. Cell 2012, 23, 1157–1166. [Google Scholar] [CrossRef] [PubMed]
  38. Gourdoupis, S.; Nasta, V.; Calderone, V.; Ciofi-Baffoni, S.; Banci, L. IBA57 Recruits ISCA2 to Form a [2Fe-2S] Cluster-Mediated Complex. J. Am. Chem. Soc. 2018, 140, 14401–14412. [Google Scholar] [CrossRef] [Green Version]
  39. Brancaccio, D.; Gallo, A.; Mikolajczyk, M.; Zovo, K.; Palumaa, P.; Novellino, E.; Piccioli, M.; Ciofi-Baffoni, S.; Banci, L. Formation of [4Fe-4S] Clusters in the Mitochondrial Iron–Sulfur Cluster Assembly Machinery. J. Am. Chem. Soc. 2014, 136, 16240–16250. [Google Scholar] [CrossRef]
  40. Brancaccio, D.; Gallo, A.; Piccioli, M.; Novellino, E.; Ciofi-Baffoni, S.; Banci, L. [4Fe-4S] Cluster Assembly in Mitochondria and Its Impairment by Copper. J. Am. Chem. Soc. 2017, 139, 719–730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Sánchez, L.A.; Gómez-Gallardo, M.; Díaz-Pérez, A.L.; Cortés-Rojo, C.; Campos-García, J. Iba57p Participates in Maturation of a [2Fe-2S]-Cluster Rieske Protein and in Formation of Supercomplexes III/IV of Saccharomyces Cerevisiae Electron Transport Chain. Mitochondrion 2019, 44, 75–84. [Google Scholar] [CrossRef]
  42. Melber, A.; Na, U.; Vashisht, A.; Weiler, B.D.; Lill, R.; Wohlschlegel, J.A.; Winge, D.R. Role of Nfu1 and Bol3 in Iron-Sulfur Cluster Transfer to Mitochondrial Clients. eLife 2016, 5, e15991. [Google Scholar] [CrossRef]
  43. Uzarska, M.A.; Przybyla-Toscano, J.; Spantgar, F.; Zannini, F.; Lill, R.; Mühlenhoff, U.; Rouhier, N. Conserved Functions of Arabidopsis Mitochondrial Late-Acting Maturation Factors in the Trafficking of Iron-sulfur Clusters. Biochim. Biophys. Acta Mol. Cell Res. 2018, 1865, 1250–1259. [Google Scholar] [CrossRef]
  44. Jain, A.; Singh, A.; Maio, N.; Rouault, T.A. Assembly of the [4Fe-4S] Cluster of NFU1 Requires the Coordinated Donation of Two [2Fe-2S] Clusters from the Scaffold Proteins, ISCU2 and ISCA1. Hum. Mol. Genet. 2020, 29, 3165–3182. [Google Scholar] [CrossRef] [PubMed]
  45. Nasta, V.; Suraci, D.; Gourdoupis, S.; Ciofi-Baffoni, S.; Banci, L. A Pathway for Assembling [4Fe-4S]2+ Clusters in Mitochondrial Iron–Sulfur Protein Biogenesis. FEBS J. 2019, 287, 2312–2327. [Google Scholar] [CrossRef] [PubMed]
  46. Suraci, D.; Saudino, G.; Nasta, V.; Ciofi-Baffoni, S.; Banci, L. ISCA1 Orchestrates ISCA2 and NFU1 in the Maturation of Human Mitochondrial [4Fe-4S] Proteins. J. Mol. Biol. 2021, 433, 166924. [Google Scholar] [CrossRef]
  47. Cameron, J.M.; Janer, A.; Levandovskiy, V.; Mackay, N.; Rouault, T.A.; Tong, W.-H.; Ogilvie, I.; Shoubridge, E.A.; Robinson, B.H. Mutations in Iron-Sulfur Cluster Scaffold Genes NFU1 and BOLA3 Cause a Fatal Deficiency of Multiple Respiratory Chain and 2-Oxoacid Dehydrogenase Enzymes. Am. J. Hum. Genet. 2011, 89, 486–495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Navarro-Sastre, A.; Tort, F.; Stehling, O.; Uzarska, M.A.; Arranz, J.A.; del Toro, M.; Labayru, M.T.; Landa, J.; Font, A.; Garcia-Villoria, J.; et al. A Fatal Mitochondrial Disease Is Associated with Defective NFU1 Function in the Maturation of a Subset of Mitochondrial Fe-S Proteins. Am. J. Hum. Genet. 2011, 89, 656–667. [Google Scholar] [CrossRef] [Green Version]
  49. Nizon, M.; Boutron, A.; Boddaert, N.; Slama, A.; Delpech, H.; Sardet, C.; Brassier, A.; Habarou, F.; Delahodde, A.; Correia, I.; et al. Leukoencephalopathy with Cysts and Hyperglycinemia May Result from NFU1 Deficiency. Mitochondrion 2014, 15, 59–64. [Google Scholar] [CrossRef]
  50. Lebigot, E.; Gaignard, P.; Dorboz, I.; Slama, A.; Rio, M.; de Lonlay, P.; Héron, B.; Sabourdy, F.; Boespflug-Tanguy, O.; Cardoso, A.; et al. Impact of Mutations within the [Fe-S] Cluster or the Lipoic Acid Biosynthesis Pathways on Mitochondrial Protein Expression Profiles in Fibroblasts from Patients. Mol. Genet. Metab. 2017, 122, 85–94. [Google Scholar] [CrossRef] [PubMed]
  51. Invernizzi, F.; Ardissone, A.; Lamantea, E.; Garavaglia, B.; Zeviani, M.; Farina, L.; Ghezzi, D.; Moroni, I. Cavitating Leukoencephalopathy with Multiple Mitochondrial Dysfunction Syndrome and NFU1 Mutations. Front. Genet. 2014, 5, 412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Tonduti, D.; Dorboz, I.; Imbard, A.; Slama, A.; Boutron, A.; Pichard, S.; Elmaleh, M.; Vallée, L.; Benoist, J.F.; Ogier, H.; et al. New Spastic Paraplegia Phenotype Associated to Mutation of NFU1. Orphanet J. Rare Dis. 2015, 10, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Ahting, U.; Mayr, J.A.; Vanlander, A.V.; Hardy, S.A.; Santra, S.; Makowski, C.; Alston, C.L.; Zimmermann, F.A.; Abela, L.; Plecko, B.; et al. Clinical, Biochemical, and Genetic Spectrum of Seven Patients with NFU1 Deficiency. Front. Genet. 2015, 6, 123. [Google Scholar] [CrossRef] [Green Version]
  54. Ferrer-Cortès, X.; Narbona, J.; Bujan, N.; Matalonga, L.; del Toro, M.; Arranz, J.A.; Riudor, E.; Garcia-Cazorla, A.; Jou, C.; O’Callaghan, M.; et al. A Leaky Splicing Mutation in NFU1 Is Associated with a Particular Biochemical Phenotype. Consequences for the Diagnosis. Mitochondrion 2016, 26, 72–80. [Google Scholar] [CrossRef]
  55. Jin, D.; Yu, T.; Zhang, L.; Wang, T.; Hu, J.; Wang, Y.; Yang, X.A. Novel NFU1 Variants Induced MMDS Behaved as Special Leukodystrophy in Chinese Sufferers. J. Mol. Neurosci. 2017, 62, 255–261. [Google Scholar] [CrossRef]
  56. De Souza, P.V.S.; Bortholin, T.; Burlin, S.; Naylor, F.G.M.; de Rezende Pinto, W.B.V.; Oliveira, A.S.B. NFU1-Related Disorders as Key Differential Diagnosis of Cavitating Leukoencephalopathy. J. Pediatr. Genet. 2018, 7, 40–42. [Google Scholar] [CrossRef]
  57. Paquay, S.; Barrea, C.; Sluysmans, T.; Vachiery, J.-L.; Loeckx, I.; Seneca, S.; Vô, C.; Nassogne, M.-C. Idiopathic Pulmonary Arterial Hypertension in Early Infancy: Excluding NFU1 Deficiency. Ann. Pediatr. Cardiol. 2019, 12, 325–328. [Google Scholar] [CrossRef]
  58. Uzunhan, T.A.; Çakar, N.E.; Seyhan, S.; Aydin, K. A Genetic Mimic of Cerebral Palsy: Homozygous NFU1 Mutation with Marked Intrafamilial Phenotypic Variation. Brain Dev. 2020, 42, 756–761. [Google Scholar] [CrossRef]
  59. Birjiniuk, A.; Glinton, K.E.; Villafranco, N.; Boyer, S.; Laufman, J.; Mizerik, E.; Scott, D.; Elsea, S.H.; Galambos, C.; Varghese, N.P.; et al. Multiple Mitochondrial Dysfunctions Syndrome 1: An Unusual Cause of Developmental Pulmonary Hypertension. Am. J. Med. Genet. 2020, 182, 755–761. [Google Scholar] [CrossRef] [PubMed]
  60. Ames, E.G.; Neville, K.L.; McNamara, N.A.; Keegan, C.E.; Elsea, S.H. Clinical Reasoning: A 12-Month-Old Child with Hypotonia and Developmental Delays. Neurology 2020, 95, 184–187. [Google Scholar] [CrossRef]
  61. Touraine, B.; Boutin, J.P.; Marion-Poll, A.; Briat, J.F.; Peltier, G.; Lobréaux, S. Nfu2: A Scaffold Protein Required for [4Fe-4S] and Ferredoxin Iron-Sulphur Cluster Assembly in Arabidopsis Chloroplasts. Plant J. 2004, 40, 101–111. [Google Scholar] [CrossRef] [PubMed]
  62. Py, B.; Gerez, C.; Angelini, S.; Planel, R.; Vinella, D.; Loiseau, L.; Talla, E.; Brochier-Armanet, C.; Garcia Serres, R.; Latour, J.-M.; et al. Molecular Organization, Biochemical Function, Cellular Role and Evolution of NfuA, an Atypical Fe-S Carrier. Mol. Microbiol. 2012, 86, 155–171. [Google Scholar] [CrossRef]
  63. Wachnowsky, C.; Wesley, N.A.; Fidai, I.; Cowan, J.A. Understanding the Molecular Basis of Multiple Mitochondrial Dysfunctions Syndrome 1 (MMDS1)—Impact of a Disease-Causing Gly208Cys Substitution on Structure and Activity of NFU1 in the Fe/S Cluster Biosynthetic Pathway. J. Mol. Biol. 2017, 429, 790–807. [Google Scholar] [CrossRef] [Green Version]
  64. Niihori, M.; Eccles, C.A.; Kurdyukov, S.; Zemskova, M.; Varghese, M.V.; Stepanova, A.A.; Galkin, A.; Rafikov, R.; Rafikova, O. Rats with Human Mutation of NFU1 Develop Pulmonary Hypertension. Am. J. Respir. Cell Mol. Biol. 2020, 62, 231–242. [Google Scholar] [CrossRef]
  65. Haack, T.B.; Rolinski, B.; Haberberger, B.; Zimmermann, F.; Schum, J.; Strecker, V.; Graf, E.; Athing, U.; Hoppen, T.; Wittig, I.; et al. Homozygous Missense Mutation in BOLA3 Causes Multiple Mitochondrial Dysfunctions Syndrome in Two Siblings. J. Inherit. Metab. Dis. 2013, 36, 55–62. [Google Scholar] [CrossRef]
  66. Baker, P.R.; Friederich, M.W.; Swanson, M.A.; Shaikh, T.; Bhattacharya, K.; Scharer, G.H.; Aicher, J.; Creadon-Swindell, G.; Geiger, E.; MacLean, K.N.; et al. Variant Non Ketotic Hyperglycinemia Is Caused by Mutations in LIAS, BOLA3 and the Novel Gene GLRX5. Brain 2014, 137, 366–379. [Google Scholar] [CrossRef] [Green Version]
  67. Imai-Okazaki, A.; Kishita, Y.; Kohda, M.; Mizuno, Y.; Fushimi, T.; Matsunaga, A.; Yatsuka, Y.; Hirata, T.; Harashima, H.; Takeda, A.; et al. Cardiomyopathy in Children with Mitochondrial Disease: Prognosis and Genetic Background. Int. J. Cardiol. 2019, 279, 115–121. [Google Scholar] [CrossRef]
  68. Kohda, M.; Tokuzawa, Y.; Kishita, Y.; Nyuzuki, H.; Moriyama, Y.; Mizuno, Y.; Hirata, T.; Yatsuka, Y.; Yamashita-Sugahara, Y.; Nakachi, Y.; et al. A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLoS Genet. 2016, 12, e1005679. [Google Scholar] [CrossRef]
  69. Bindu, P.S.; Sonam, K.; Chiplunkar, S.; Govindaraj, P.; Nagappa, M.; Vekhande, C.C.; Aravinda, H.R.; Ponmalar, J.J.; Mahadevan, A.; Gayathri, N.; et al. Mitochondrial Leukoencephalopathies: A Border Zone between Acquired and Inherited White Matter Disorders in Children? Mult. Scler. Relat. Disord. 2018, 20, 84–92. [Google Scholar] [CrossRef] [Green Version]
  70. Nikam, R.M.; Gripp, K.W.; Choudhary, A.K.; Kandula, V. Imaging Phenotype of Multiple Mitochondrial Dysfunction Syndrome 2, a Rare BOLA3-Associated Leukodystrophy. Am. J. Med. Genet. 2018, 176, 2787–2790. [Google Scholar] [CrossRef]
  71. Nishioka, M.; Inaba, Y.; Motobayashi, M.; Hara, Y.; Numata, R.; Amano, Y.; Shingu, K.; Yamamoto, Y.; Murayama, K.; Ohtake, A.; et al. An Infant Case of Diffuse Cerebrospinal Lesions and Cardiomyopathy Caused by a BOLA3 Mutation. Brain Dev. 2018, 40, 484–488. [Google Scholar] [CrossRef]
  72. Stutterd, C.A.; Lake, N.J.; Peters, H.; Lockhart, P.J.; Taft, R.J.; van der Knaap, M.S.; Vanderver, A.; Thorburn, D.R.; Simons, C.; Leventer, R.J. Severe Leukoencephalopathy with Clinical Recovery Caused by Recessive BOLA3 Mutations. JIMD Rep. 2019, 43, 63–70. [Google Scholar] [CrossRef]
  73. Meldau, S.; Fratter, C.; Bhengu, L.N.; Sergeant, K.; Khan, K.; Riordan, G.T.; Berman, P.A.M. Pitfalls of Relying on Genetic Testing Only to Diagnose Inherited Metabolic Disorders in Non-Western Populations-5 Cases of Pyruvate Dehydrogenase Deficiency from South Africa. Mol. Genet. Metab. Rep. 2020, 24, 100629. [Google Scholar] [CrossRef]
  74. Uzarska, M.A.; Nasta, V.; Weiler, B.D.; Spantgar, F.; Ciofi-Baffoni, S.; Saviello, M.R.; Gonnelli, L.; Mühlenhoff, U.; Banci, L.; Lill, R. Mitochondrial Bol1 and Bol3 Function as Assembly Factors for Specific Iron-Sulfur Proteins. eLife 2016, 5, e16673. [Google Scholar] [CrossRef]
  75. Torraco, A.; Ardissone, A.; Invernizzi, F.; Rizza, T.; Fiermonte, G.; Niceta, M.; Zanetti, N.; Martinelli, D.; Vozza, A.; Verrigni, D.; et al. Novel Mutations in IBA57 Are Associated with Leukodystrophy and Variable Clinical Phenotypes. J. Neurol. 2017, 264, 102–111. [Google Scholar] [CrossRef]
  76. Saudino, G.; Suraci, D.; Nasta, V.; Ciofi-Baffoni, S.; Banci, L. Molecular Basis of Multiple Mitochondrial Dysfunctions Syndrome 2 Caused by Cys59tyr Bola3 Mutation. Int. J. Mol. Sci. 2021, 22, 4848. [Google Scholar] [CrossRef]
  77. Yu, Q.; Tai, Y.; Tang, Y.; Zhao, J.; Negi, V.; Culley, M.K.; Pilli, J.; Sun, W.; Brugger, K.; Saggar, R.; et al. BOLA3 Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. Circulation 2020, 139, 2238–2255. [Google Scholar] [CrossRef]
  78. Ajit Bolar, N.; Vanlander, A.V.; Wilbrecht, C.; van der Aa, N.; Smet, J.; de Paepe, B.; Vandeweyer, G.; Kooy, F.; Eyskens, F.; de Latter, E.; et al. Mutation of the Iron-Sulfur Cluster Assembly Gene IBA57 Causes Severe Myopathy and Encephalopathy. Hum. Mol. Genet. 2013, 22, 2590–2602. [Google Scholar] [CrossRef]
  79. Lossos, A.; Stümpfig, C.; Stevanin, G.; Gaussen, M.; Zimmerman, B.-E.; Mundwiller, E.; Asulin, M.; Chamma, L.; Sheffer, R.; Misk, A.; et al. Fe/S Protein Assembly Gene IBA57 Mutation Causes Hereditary Spastic Paraplegia. Neurology 2015, 84, 659–667. [Google Scholar] [CrossRef]
  80. Debray, F.-G.; Stümpfig, C.; Vanlander, A.V.; Dideberg, V.; Josse, C.; Caberg, J.-H.; Boemer, F.; Bours, V.; Stevens, R.; Seneca, S.; et al. Mutation of the Iron-Sulfur Cluster Assembly Gene IBA57 Causes Fatal Infantile Leukodystrophy. J. Inherit. Metab. Dis. 2015, 38, 1147–1153. [Google Scholar] [CrossRef]
  81. Ishiyama, A.; Sakai, C.; Matsushima, Y.; Noguchi, S.; Mitsuhashi, S.; Endo, Y.; Hayashi, Y.K.; Saito, Y.; Nakagawa, E.; Komaki, H.; et al. IBA57 Mutations Abrogate Iron-Sulfur Cluster Assembly Leading to Cavitating Leukoencephalopathy. Neurol. Genet. 2017, 3, e184. [Google Scholar] [CrossRef] [Green Version]
  82. Hamanaka, K.; Miyatake, S.; Zerem, A.; Lev, D.; Blumkin, L.; Yokochi, K.; Fujita, A.; Imagawa, E.; Iwama, K.; Nakashima, M.; et al. Expanding the Phenotype of IBA57 Mutations: Related Leukodystrophy Can Remain Asymptomatic. J. Hum. Genet. 2018, 63, 1223–1229. [Google Scholar] [CrossRef]
  83. Liu, M.; Zhang, J.; Zhang, Z.; Zhou, L.; Jiang, Y.; Wang, J.; Xiao, J.; Wu, Y. Phenotypic Spectrum of Mutations in IBA57, a Candidate Gene for Cavitating Leukoencephalopathy. Clin. Genet. 2018, 93, 235–241. [Google Scholar] [CrossRef]
  84. Zhang, J.; Liu, M.; Zhang, Z.; Zhou, L.; Kong, W.; Jiang, Y.; Wang, J.; Xiao, J.; Wu, Y. Genotypic Spectrum and Natural History of Cavitating Leukoencephalopathies in Childhood. Pediatr. Neurol. 2019, 94, 38–47. [Google Scholar] [CrossRef]
  85. Hu, C.; Li, X.; Zhao, L.; Shi, Y.; Zhou, S.; Wu, B.; Wang, Y. Clinical and Molecular Characterization of Pediatric Mitochondrial Disorders in South of China. Eur. J. Med. Genet. 2020, 63, 103898. [Google Scholar] [CrossRef]
  86. Al-Hassnan, Z.N.; Al-Dosary, M.; Alfadhel, M.; Faqeih, E.A.; Alsagob, M.; Kenana, R.; Almass, R.; Al-Harazi, O.S.; Al-Hindi, H.; Malibari, O.I.; et al. ISCA2 Mutation Causes Infantile Neurodegenerative Mitochondrial Disorder. J. Med. Genet. 2015, 52, 186–194. [Google Scholar] [CrossRef]
  87. Alazami, A.M.; Patel, N.; Shamseldin, H.E.; Anazi, S.; Al-Dosari, M.S.; Alzahrani, F.; Hijazi, H.; Alshammari, M.; Aldahmesh, M.A.; Salih, M.A.; et al. Accelerating Novel Candidate Gene Discovery in Neurogenetic Disorders via Whole-Exome Sequencing of Prescreened Multiplex Consanguineous Families. Cell Rep. 2015, 10, 148–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Alfadhel, M.; Nashabat, M.; Alrifai, M.T.; Alshaalan, H.; al Mutairi, F.; Al-Shahrani, S.A.; Plecko, B.; Almass, R.; Alsagob, M.; Almutairi, F.B.; et al. Further Delineation of the Phenotypic Spectrum of ISCA2 Defect: A Report of Ten New Cases. Eur. J. Paediatr. Neurol. 2018, 22, 46–55. [Google Scholar] [CrossRef]
  89. Alaimo, J.T.; Besse, A.; Alston, C.L.; Pang, K.; Appadurai, V.; Samanta, M.; Smpokou, P.; McFarland, R.; Taylor, R.W.; Bonnen, P.E. Loss-of-Function Mutations in ISCA2 Disrupt 4Fe-4S Cluster Machinery and Cause a Fatal Leukodystrophy with Hyperglycinemia and MtDNA Depletion. Hum. Mutat. 2018, 39, 537–549. [Google Scholar] [CrossRef] [Green Version]
  90. Alfadhel, M. Multiple Mitochondrial Dysfunctions Syndrome 4 Due to ISCA2 Gene Defects: A Review. Child Neurol. Open 2019, 6, 2329048X1984737. [Google Scholar] [CrossRef] [Green Version]
  91. Toldo, I.; Nosadini, M.; Boscardin, C.; Talenti, G.; Manara, R.; Lamantea, E.; Legati, A.; Ghezzi, D.; Perilongo, G.; Sartori, S. Neonatal Mitochondrial Leukoencephalopathy with Brain and Spinal Involvement and High Lactate: Expanding the Phenotype of ISCA2 Gene Mutations. Metab. Brain Dis. 2018, 33, 805–812. [Google Scholar] [CrossRef]
  92. Eidi, M.; Garshasbi, M. A Novel ISCA2 Variant Responsible for an Early-Onset Neurodegenerative Mitochondrial Disorder: A Case Report of Multiple Mitochondrial Dysfunctions Syndrome 4. BMC Neurol. 2019, 19, 153. [Google Scholar] [CrossRef] [Green Version]
  93. Hartman, T.G.; Yosovich, K.; Michaeli, H.G.; Blumkin, L.; Ben-Sira, L.; Lev, D.; Lerman-Sagie, T.; Zerem, A. Expanding the Genotype-Phenotype Spectrum of ISCA2-Related Multiple Mitochondrial Dysfunction Syndrome-Cavitating Leukoencephalopathy and Prolonged Survival. Neurogenetics 2020, 21, 243–249. [Google Scholar] [CrossRef]
  94. Beilschmidt, L.K.; Puccio, H.M. Mammalian Fe-S Cluster Biogenesis and Its Implication in Disease. Biochimie 2014, 100, 48–60. [Google Scholar] [CrossRef]
  95. Shukla, A.; Hebbar, M.; Srivastava, A.; Kadavigere, R.; Upadhyai, P.; Kanthi, A.; Brandau, O.; Bielas, S.; Girisha, K.M. Homozygous p.(Glu87Lys) Variant in ISCA1 Is Associated with a Multiple Mitochondrial Dysfunctions Syndrome. J. Hum. Genet. 2017, 62, 723–727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Shukla, A.; Kaur, P.; Girisha, K. Report of the Third Family with Multiple Mitochondrial Dysfunctions Syndrome 5 Caused by the Founder Variant p.(Glu87Lys) in ISCA1. J. Pediatr. Genet. 2018, 7, 130–133. [Google Scholar] [CrossRef]
  97. Torraco, A.; Stehling, O.; Stümpfig, C.; Rösser, R.; de Rasmo, D.; Fiermonte, G.; Verrigni, D.; Rizza, T.; Vozza, A.; di Nottia, M.; et al. ISCA1 Mutation in a Patient with Infantile-Onset Leukodystrophy Causes Defects in Mitochondrial [4Fe-4S] Proteins. Hum. Mol. Genet. 2018, 27, 2739–2754. [Google Scholar] [CrossRef] [PubMed]
  98. Lebigot, E.; Hully, M.; Amazit, L.; Gaignard, P.; Michel, T.; Rio, M.; Lombès, M.; Thérond, P.; Boutron, A.; Golinelli-Cohen, M.P. Expanding the Phenotype of Mitochondrial Disease: Novel Pathogenic Variant in ISCA1 Leading to Instability of the Iron-Sulfur Cluster in the Protein. Mitochondrion 2020, 52, 75–82. [Google Scholar] [CrossRef]
  99. Finsterer, J.; Zarrouk-Mahjoub, S.; Daruich, A. The Eye on Mitochondrial Disorders. J. Child Neurol. 2016, 31, 652–662. [Google Scholar] [CrossRef] [Green Version]
Biomedicines 09 00989 g001 550
Figure 1. Schema of the main steps of Fe-S protein maturation. Only the mitochondrial ISC machinery components are detailed. Mitoferrin (MFRN) is involved in iron entry in mitochondria. Proteins in yellow frames are needed for cysteine desulfuration and [2Fe-2S] cluster de novo assembly on the ISCU. After its transfer on GLRX5, the [2Fe-2S] cluster is exported to the cytosol (for extra-mitochondrial Fe-S protein maturation) and is inserted to mitochondrial [2Fe-2S] proteins or is taken in charge by proteins essential for [4Fe-4S] cluster biosynthesis and the maturation of mitochondrial [4Fe-4S] containing proteins. Proteins involved in MMDS pathologies are framed in red.
Figure 1. Schema of the main steps of Fe-S protein maturation. Only the mitochondrial ISC machinery components are detailed. Mitoferrin (MFRN) is involved in iron entry in mitochondria. Proteins in yellow frames are needed for cysteine desulfuration and [2Fe-2S] cluster de novo assembly on the ISCU. After its transfer on GLRX5, the [2Fe-2S] cluster is exported to the cytosol (for extra-mitochondrial Fe-S protein maturation) and is inserted to mitochondrial [2Fe-2S] proteins or is taken in charge by proteins essential for [4Fe-4S] cluster biosynthesis and the maturation of mitochondrial [4Fe-4S] containing proteins. Proteins involved in MMDS pathologies are framed in red.
Biomedicines 09 00989 g001
Biomedicines 09 00989 g002 550
Figure 2. Schematic of NFU1 protein (NP_001002755) with reported variants. Missense and truncating variants are indicated above and intragenic deletions below the protein structure. Schematic secondary structure shows α-helix (grey), β-strand (black), and turn (grey and black crosshatchings). The mitochondrial targeted sequence corresponds to the 10 first residues.
Figure 2. Schematic of NFU1 protein (NP_001002755) with reported variants. Missense and truncating variants are indicated above and intragenic deletions below the protein structure. Schematic secondary structure shows α-helix (grey), β-strand (black), and turn (grey and black crosshatchings). The mitochondrial targeted sequence corresponds to the 10 first residues.
Biomedicines 09 00989 g002
Biomedicines 09 00989 g003 550
Figure 3. Schematic of BOLA3 protein (NP_997717) with reported variants. Missense variants are indicated in italic. Schematic secondary structure shows α-helix (grey), β-strand (black), and turn (grey and white crosshatchings) (adapted from UniprotKB, protein Q53S33). A mitochondrial targeted sequence has not yet been formally identified.
Figure 3. Schematic of BOLA3 protein (NP_997717) with reported variants. Missense variants are indicated in italic. Schematic secondary structure shows α-helix (grey), β-strand (black), and turn (grey and white crosshatchings) (adapted from UniprotKB, protein Q53S33). A mitochondrial targeted sequence has not yet been formally identified.
Biomedicines 09 00989 g003
Biomedicines 09 00989 g004 550
Figure 4. Schematic of IBA57 protein (NP_001010867) with reported variants. Schematic secondary structure shows α-helix (grey), β-strand (black), and turn (grey and white crosshatches) (adapted from UniprotKB, protein Q5T440).
Figure 4. Schematic of IBA57 protein (NP_001010867) with reported variants. Schematic secondary structure shows α-helix (grey), β-strand (black), and turn (grey and white crosshatches) (adapted from UniprotKB, protein Q5T440).
Biomedicines 09 00989 g004
Biomedicines 09 00989 g005 550
Figure 5. Schematic of ISCA2 protein (NP_919255) with reported pathogenic variants. Mitochondrial target sequencing encompassed residues 1 to 8 (grey and white crosshatches) (adapted from UniprotKB, protein Q86U28).
Figure 5. Schematic of ISCA2 protein (NP_919255) with reported pathogenic variants. Mitochondrial target sequencing encompassed residues 1 to 8 (grey and white crosshatches) (adapted from UniprotKB, protein Q86U28).
Biomedicines 09 00989 g005
Table
Table 1. Reported patients with MMDS type 1.
Table 1. Reported patients with MMDS type 1.
Ref.Nb of Patients (Nb and Origin of Families)Age at Onset/Age at DeathMetabolic
Findings		Impaired Mitochondrial ProteinsPulmonary
Hypertension		Clinical FeatureBrain MRI/
Spectroscopy		Genotype (NFU1:NM_001002755.4)
[47]3 (1F, Mexico)Neonatal/1st mHigh lactate and glycine levels (bl)Complexes I + III, II, IV, PDH, KGDH, lipoylated proteinsNoFD, hypotonia, respiratory failureNAc.[545G > A]; [545G > A]; p.[(Arg182Gln)]; [(Arg182Gln)]
[48]10 (9F incl. 4F of basque origin)1–9 m/2–15 mHigh lactate and glycine (bl and CSF) and amino-adipate, α-KG, 2 ketoadipate, tyglyglycine (ur) levelsPDH, lipoylated proteinsYes (7/10)FD (6/10), dysmorphia (1/10), skills regression (6/10)LD and semioval necrosis (n = 1), semioval center and cerebellum lesions (n = 1), cerebral atrophy (n = 1)c.[622G > T]; [622G > T], p.[(Gly208Cys)]; [(Gly208Cys)] (9/10)
c.[622G > T]; [545 + 5G > A], p.[(Gly208Cys)]; [Pro183Glnfs*10] (1/10)
[49,50]1 (France)5 m/3 yHigh lactate (bl), glycine (bl and CSF) and α-KG (ur) levelsComplexes I, II, PDH, KGDH, lipoylated proteinsIn acute episodesSevere DR, transient MD, myoclonies, hypotoniaProgressive LE, kysts in PV WM and in CCc.[565G > A]; [622G > T], p.[(Gly189Arg)]; [(Gly208Cys)]
[51]1 (Italia)7 m/18 mHigh lactate, pyruvate, glycine (bl), succinate, fumarate, glutarate (ur) levelsComplexes I, II, IV, PDHNoFD, spasticity, severe DRDiffuse LE (deep WM), cavitations/peak of lactatec.[565G > A]; [629G > T], p.[(Gly189Arg)]; [(Cys210Phe)]
[52]1 (unknown)18 m/alive at 30 yHigh lactate, pyruvate (bl), glycine (bl and CSF) levelsComplexes II, IV, PDH, KGDH,NoSpastic tetraparesis, scoliosis, DR after fever, MSNPV WM and CC abnormal signal, CC atrophy/reduced NAA peak, mild lactate, and high choline peaksc.[146del]; [565G > A], p.[(Pro49Leufs*8)]; [(Gly189Arg)]
[53]7 (5F, Germany (G), Romania/Serbia (RS) Pakistan (P), Belgium (B))Birth–5 m/3 m–30 mHigh lactate (6/7), glycine (7/7) levels (bl)Complexes I (2/5), II (3/3), IV (1/4), PDH (5/5)Yes (4/7)Muscular hypotonia (6/7), apnea (4/7), FD (4/7), tubulopathy (1/7), CMP (2/7)LE (3/4) affecting PV (2/4), capsula interna (3/4), or upper cervical cord (1/4); hypomyelination (2/4)g.[69400462C > A]; [69592691_69648327del], p.[(Gly208Cys)]; [?] (G)
c.[565G > A]; [568G > A], p.[(Gly189Arg)]; [(Gly190Arg)] (G)
c.[544C > T]; [?], p.[(Arg182Trp)]; [?]) (RS)
c.[302 + 3A > G]; [302 + 3A > G], p.[(Val56Glyfs∗9)]; [(Val56Glyfs∗9)] (3/7, P)
c.[62G > C]; [622G > T], p.[(Arg21Pro)]; [(Gly208Cys)] (B)
[54]2 (2F, unknown)2–15 m/14–19 mHigh lactate (CSF) and glycine (ur, bl and CSF), 2-amino and 2-hydroxyadipate, tyglylglycine, isovalerylglycine (ur) levelsGCS (1/1), lipoylated proteins (2/2), CII + CIII (1/1)Yes (1/2)Severe spasticity, axial hypotonia, apnea, DRcysts in temporal lobes with glycine peak (1/2), WM spongiosis, PV WM and CC LD (1/2)c.[622G> T]; [545 + 5G > A], p.[(Gly208Cys)]; [Pro183Glnfs*10]
[55]2 (2F, China)3–4 m/3–4 mHigh lactate level (bl, ur, 1/2), normal glycine levels (2/2)NAYes (1/2)DR (2/2), seizures, muscular hypertonia, and ascitis (1/2)LD in subcortical WM (internal—external capsule, CC, medulla) or midbrain, thalamus, lateral ventricle, and centrum ovalec.[545 + 5G > A]; [545 + 5G > A], p.[(Pro183Glnfs*10)]; [(Pro183Glnfs*10)]
c.[721G > T]; [303_369del], p.[(Val241Phe)]; [?]
[50]3 (3F, unknown)3–3, 5–7 m/4 m to 3 yHigh lactate (bl 3/3) and glycine (bl:2/2, ur:1/2 and CSF:1/1), fumarate (1/1), 2-amino-adipate (pl) or 2 keto-adipate (ur) levelsComplexes I (3/3), II (2/3), IV (1/3), PDH (3/3), KGDH (2/3), lipoylated proteins (2/3)Yes (1/3)Seizures (2/3), spasticity (1/3), apnea (1/3), PMD (2/3)Normal (1/3), WM abnormalities (1/3), necrotizing LD (1/3)
/lactate peak (1/2)		c.[146del],
[303–1988_c.369 + 1021del], p.[(Pro49Leufs*8)]; [?]
c.[622G > T]; [629G > T], p.[(Gly208Cys)]; [(Cys210Phe)]
c.[179T > G]; [179T > G], p.[(Phe60Cys)]; [(Phe60Cys)]
[56]1 (Brazil)4 m/8 mHigh lactate (bl, ur) and glutaric acid (ur) levelsNANo (normal ECG)Severe hypotonia, spastic tetraparesis, DR, lethargyCavitating cystic LE (PV, deep, subcortical areas)c.[545G > A]; [622G > T],
p.[(Arg182Gln)]; [(Gly208Cys)]
[57]1 (Portugal)1 m/10 mElevated glycine level (bl)NASevere (onset)FD, DR, seizures, spasticity, and axial hypotoniaWM necrotic areas, PV WM abnormal signalsc.[622G > T]; [622G > T], p.[(Gly208Cys)]; [(Gly208Cys)]
[58]1 (Turkey)23 m/alive at 41 mHigh lactate and glycine (bl) levelsNANo (normal ECG)Episodes of DR and legs spasticity after feverFrontal PV cysts and frontal WM and CC hyperintensity,c.[565G > A]; [565G > A], p.[(Gly189Arg)]; [(Gly189Arg)]
[59]2 (1F, Guatemala)2–3 m/5–7 mHigh lactate (bl) and α-KG (ur) levelsE3 and PDHYes (with cardiomegaly or dilated CMP)FD, emesis, developmental delay, spasticityNAc.[544C > T]; [622G > T],
p.[(Arg182Trp)]; [(Gly208Cys)]
[60]1 (unknown)7 m/12 mHigh glycine (bl, CSF) and lactate (CSF) levelsNAYes (mild)PMD, bradypnea, hypotoniaBilateral basal ganglia, thalami, frontoparietal WM, cerebral peduncles, spinal cord abnormal signals/lactate peak (MRS)c.[299C > G]; [398T > C],
p.[(Ala100Gly)]; [(Leu133Pro)]
Bl: blood; CC: corpus callosum; CMP: cardiomyopathy; CSF: cerebrospinal fluid; DR: developmental regression; ECG: electrocardiogram; F: families; FD: feeding difficulties; GCS: glycine cleavage system; α-KG: alpha-ketoglutarate; LD: leukodystrophy; LE: leukoencephalopathy; m: month(s); MD: motor deficiency; MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy; MSN: motor-sensory neuropathy; NA: not available; NAA: N-acetylaspartate; PMD: psychomotor delay; PV: periventricular; ur: urine; WM: white matter; y: year(s).
Table
Table 2. Reported patients with MMDS type 2.
Table 2. Reported patients with MMDS type 2.
Ref.Nb of Patients (Nb and Origin of Families)Age at Onset/Age at DeathMetabolic FindingsImpaired Mitochondrial ProteinsCardiomyo- pathyClinical FeatureBrain MRI/SpectroscopyGenotype (BOLA3:NM_212552.2)
[47]1 (East Indian)4 m/11 mHigh glycine level (bl, ur)Complexes I and II, PDH, lipoylated proteinDilatedFD, lethargy, respiratory distress, HMG, DDNAc.[123dupA]; [123dupA], p.[(Glu42Argfs*13)]; [(Glu42Argfs*13)]
[65]2 (1F, unknown)<1 m/3 mHigh pyruvate (bl, ur), lactate (bl, ur), and glycine levels (bl)Complexes I, II, IV, PDH, lipoylated proteinHyper-trophicFD, SE, hypotonia, progressive encephalopathyDelayed myelination, supra-, PV, and bifrontal and biparietal hyperintense lesions (T2)c.[200T > A]; [200T > A], p.[(Ile67Asn)]; [(Ile67Asn)]
[66]3 (3F: Australia, India, African- American)6–8 m/7 m, 22 m, 11 yHigh lactate (bl), glycine (CSF) levelsComplex II (n = 1/3), PDH (n = 1/2), lipoylated protein (n = 2/2), GCS (n = 3/3)Hyper-trophic (n = 2/2)FD, SE (n = 1/3), Myoclonus (2/3), SP and severe PMDD (1/3), skills regression (2/3), optic atrophy (n = 2/3)PV WM and spinal cord lesions (n = 1/3), subcortical fibers lesions (n = 1/3) LD (n = 2/3), cerebral and cerebellar atrophy (n = 1/3)c.[136C > T]; [136C > T], p.[(Arg46*)]; [(Arg46*)]
[67,68]4 (4F, Japan)<1, 2, 6 m/3–11 mMetabolic acidosisCombined complex deficiencies (n = 4/4)Hyper-trophic (n = 3/4)Renal, respiratory, and/or liver failures, SE, FCMD (n = 1)NAc.[287A > G]; [287A > G], p.[(His96Arg)]; [(His96Arg)] (3/4)
c.[225_229del]; [287A > G], p.[(Lys75Asnfs*9)]; [(His96Arg)]
[50]2 (1F, India)5–7 m/8 mHigh pyruvate (bl), lactate (bl, CSF), glycine (bl, CSF, ur) levelsComplexes I, II, IV, PDH, lipoylated proteinNoFD, tetraparesis, hypotonia, PMDDDiffuse demyelination/lactate peakc.[136C > T]; [136C > T], p.[(Arg46*)]; [(Arg46*)]
[69]2 (unknown)18 m/alive at 12 y (n = 1)NANANASPT (n = 1/2), skills regression, gait difficultyPV and deep WM or fronto-parietal lesions/lactate peak (n = 1/1)c.[295C > T]; [295C > T], p.[(Arg99Trp)]; [(Arg99Trp)]
[70]1 (unknown)8 m/15 mHigh lactate (bl), tiglylglycine (ur) levelsPDH, lipoylated proteinNAFD, hypertonicity then hypotonia, nystagmusSymmetric ovoid areas and CC, cervical cord regions abnormal signal. PV, deep, subcortical WM lesions/lactate peakc.[200T > A]; [220_222del],
p.[(Ile67Asn)]; [(Glu74del)]
[71]1 (Japan)6 m/10 mHigh lactate (bl, CSF), glycine (bl) levelsComplexes I, II, IVHypertrophicFD, SE, eyelid movements, hypotonia, skill regressionDeep WM to spinal cord lesionsc.[287A > G]; [287A > G], p.[(His96Arg); [(His96Arg)]
[72]1 (England)18 m/alive at 8 yNormal lactate (bl), high glycine (bl, ur) levelsPDH, normal RCC activity but low quantity of protein in complexes I and IINoAtaxia, acute hemiparesis, cognitive regression, congenital hypothyroidismsubcortical WM, basal ganglia, brainstem and cerebellum abnormal signal and dysmyelinationc.[136C > T]; [176G > A], p.[(Arg46*)]; [(Cys59Tyr)]
[73]1 (South Africa)7 m/17 mHigh lactate (bl), glycine (ur) levelsPDHNoSudden skill regression, floppiness, encephalopathyDemyelinationc.[159dupT]; [159dupT], p.[(Asp54*)]; [(Asp54*)]
Bl: blood; CC: corpus callosum; CSF: cerebrospinal fluid; DD: developmental delay; F: families; FCMD: Fukuyama congenital muscular dystrophy; FD: feeding difficulties; HMG: hepatomegaly; m: month(s); MRI: Magnetic resonance imaging; NA: not available; PDH: pyruvate dehydrogenase complex; PMDD: psycho-motor developmental delay; PV: periventricular; RCC: respiratory chain complexes; SE: seizures; SP: spasticity; SPT: spastic tetraparesis; Ur: urine; WM: white matter; y: year(s).
Table
Table 3. Reported cases with MMDS type 3.
Table 3. Reported cases with MMDS type 3.
Ref.Nb of Patients (Nb and Origin of Families)Age at Onset/Age at DeathMetabolic FindingsImpaired Mitochondrial ProteinsOphthalmological FindingsClinical FeatureBrain MRI/SpectroscopyGenotype (IBA57: NM_001010867)
[78]2 (1F, Morocco)Antenatal/1 d, 15 dIncreased lactate (bl) and glycine (bl, CSF) levelsComplexes I, II, and IV, lipoylated proteins, IBA57 proteinNAPolyhydramnios, microcephaly, severe hypotoniaCerebral atrophy, polymicrogyria, CC hypoplasiac.[941A > C]; [941A > C],
p.[(Gln314Pro)]; [(Gln314Pro)]
[79]12 (1F, Palestine)After 3 y/alive (12–65 y)Normal lactate levelComplexes I, II, lipoylated proteinsOptic atrophyPeripheral neuropathy, progressive spastic paraplegiaHyperintensity in WM, cystic cavitation. Cerebellar, CC, CSC atrophyc.[678A > G]; [678A > G],
p.[Gly227Valfs]; [Gly227Valfs]
[80]1 (Morocco)6 m/17 mIncreased lactate and glycine levels (bl, CSF)Complexes I, II, and IV, lipoylated proteins,NAFD with vomiting, opistothonos crises, progressive hypotonia, skills regressionCentral and PV LE involving CC IC, USC, and cerebellar WM/lactate peakc.[436C > T]; [436C > T],
p.[(Arg146Trp)]; [(Arg146Trp)]
[50]2 (2F, unknown)3 w–8 m/2–11 mHigh lactate level (bl, CSF)Complexes I, II, lipoylated proteins, PDHcNAHypotonia, with recurrent myoclonus, pyramidal syndrome, apneaPV LD, myelination delayc.[335T > G]; [437G > C], p.[(Leu112Trp)]; [(Arg146Pro)] c.[316A > G]; [738C > G]; p.[(Thr106Ala)]; [(Asn246Lys)]
[81]3 (2F, unknown)11 m–2 y/alive at 6–7 yIntermittent high lactate level (bl, CSF)Complexes I, II, lipoylated proteins, IBA57 protein levelNASpasticity, axial hypotonia, PMRPV and CC LE with cysts or cavitationc.[323A > C]; [940C > T], p.[(Tyr108Ser)]; [(Gln314*)]
c.[323A > C]; [150C > A], p.[(Tyr108Ser)]; [(Cys50*)]
[75]4 (4F, Tunisia, unknown)4–18 m/2 y (n = 2) or alive at 12–16 yHigh lactate and pyruvate levels (bl or CSF, 3/4)Complex II (fib: 3/4, muscle 2/3)), complex I fib (1/4)Nystagmus (2/4), abnormal VEP (3/3)Severe PMR (4/4), FD (3/4), spastic tetraparesis (3/4), severe hypotonia (1/4), epilepsy (1/4)Cavitating LE or LD (3/4), cerebral and cerebellar WM involvement (3/4)/lactate peak (3/4)c.[586T > G]; [c.686C > T], p.[(Trp196Gly]; [Pro229Leu]
c.[87insGCCCAAGGTGC]; [313C > T], p.[(Arg30Alafs)]; [(Arg105Trp)]
c.[706C > T]; [706C > T], p.[(Pro236Ser)]; [(Pro236Ser)]
c.[316A > G]; [757G > C]; p.[(Thr106Ala]; [(Val253Leu)]
[69]2 (2F, unknown))18–20 m/alive at 19–31 mNANANAMilestones loss, difficulty in standing, progressive quadriparesisLarge hyperintense lesions in FP WM (2/2), in CC, and multiple WM cysts (1/2)c.[738C > G]; [802C > T], p.[(Asn246Lys)]; [(Arg268Cys)]
c.[656A > G]; [706C > T], p.[(Tyr219Cys)]; [(Pro236Ser)]
[82]3 (2F, Israel, Japan)7–20 m/alive at 7–19–29 yNormal lactate level (1/1)Normal RCC activity (1/1)Reduced vision with pale discs (2/3), pendular nystagmus (1/3); no (1/3)No neurological signs (1/3), spasticity with learning disabilities (1/3), PMR, spasticity, seizures, severe hypotonia and PMD (1/3)PV WM hypersignal, thin optic nerves, PV rarefaction with thin CC (2/3), progressive WM atrophy, and cystic degeneration (1/3)c.[335T > C]; [c.588dup], p.[(Leu112Ser)]; [(Arg197Alafs)]
c.[386A > T]; [731A > C], p.[(Asp129Val)]; [(Glu244Ala)]
[83]11 (9F, China)5–15 m/Alive at 11 m to 10 yHigh blood lactate level (2/11)NANystagmus (3/11), visual impairment 3/11Spasticity and motor regression (11/11), seizures (2/11)Cavitating lesions in the frontal, parieto-occipital WM, CC (7/11), temporal (4/11), cerebellar, or IC (1/11)c.[286T > C]; [316A > G], p.[(Tyr96His)]; [(Thr106Ala)] (n = 2)
c.[701A > G]; [782T > C], p.[(Asp234Gly)]; [(Ile261Thr)]
c.[286T > C]; [697C > T], p.[(Tyr96His)]; [(Arg223*)] (n = 3)
c.[188G > A]; [286T > C], p.[(Gly63Asp)]; [(Tyr96His)]
c.[286T > C]; [307C > T], p.[(Tyr96His)]; [(Gln103*)] (n = 2)
c.[286T > C]; [754G > T], p.[(Tyr96His)]; [(Gly252Cys)]
c.[22C > T]; [286T > C], p.[(Arg8*)]; [(Tyr96His)]
[84]17 (unknown, China)NANANAVisual impairment (8/17)NANo progressive cavitating LE: involving diffuse (12/17 or deep WM (5/17),c.[22C > T]; [286T > C], p.[(Arg8*)]; [(Tyr96His)]
c.[188G > A]; [286T > C], p.[(Gly63Asp)]; [(Tyr96His)]
(n = 2)
c.[236C > T]; [307C > T], p.[(Pro79Leu)]; [(Gln103*)]
c.[286T > C]; [697C > T], p.[(Tyr96His)]; [(Arg223*)] (n = 4)
c.[286T > C]; [307C > T], p.[(Tyr96His)]; [(Gln103*)]
(n = 2)
c.[286T > C]; [316A > G], p.[(Tyr96His)]; [(Thr106Ala)] (n = 2)
c.[286T > C]; [522_523del], p.[(Tyr96His)]; [(Leu175Alafs)]
c.[286T > C]; [589_590del], p.[(Tyr96His)]; [(Arg197Alafs)]
c.[286T > C]; [754G > T], p.[(Tyr96His)]; [(Gly252Cys)]
c.[286T > C]; [1053G > A], p.[(Tyr96His)]; [(Trp351*)]
c.[701A > G]; [782T > C], p.[(Asp234Gly)]; [(Ile261Thr)]
[85]2 (2F, China)5–15 m/unknownNormal lactate levelNANAPMRLEc.[286T > C]; [697C > T], p.[(Tyr96His)]; [(Arg223*)]
c.[286T > C]; [589_590del], p.[(Tyr96His)]; [(Arg197Alafs)]
Bl: blood; CC: corpus callosum; CSC: cervical spinal cord; CSF: cerebrospinal fluid; d: day(s); F: families; FD: feeding difficulties; fib: fibroblast; FP: frontoparietal; IC: internal capsule; LD/LE: leuko-dystrophy/encephalopathy; m: month(s); MRI: Magnetic resonance imaging; NA: not available; PMR/D: psychomotor regression/delay; PV: periventricular; RCC: respiratory chain complexes; USC: upper spinal cord; VEP: visual evoked potentials; w: week(s); WM: white matter; y: year(s).
Table
Table 4. Reported cases with MMDS type 4.
Table 4. Reported cases with MMDS type 4.
Ref.Nb of Patients (Nb and Origin of Families)Age at Onset/Age at DeathMetabolic FindingsImpaired Mitochondrial ProteinsOphthalmological FindingsClinical FeatureBrain MRI/SpectroscopyGenotype (ISCA2: NM_194279)
[86]6 (5F, Saudi Arabia)3–7 m/11 m to 5 y (n = 4), alive (13–16 m, n = 2)NegativeComplex IOptic atrophy (6/6)Spasticity, severe PMRLesions in cerebral (PV region to U fibers) and cerebellar WM, CC, internal capsulec.[229G > A]; [229G > A], p.[(Gly77Ser)]; [(Gly77Ser)]
[87]1 (Saudi Arabia)NANANANANeurodegenerationLesions in WM/Lactate peakc.[229G > A]; [229G > A], p.[(Gly77Ser)]; [(Gly77Ser)]
[50]2 (2F, unknown)2 d, NA/12 d (n = 1), alive at 12 yElevated lactate (bl, CSF 1/2)Complexes I, II, lipoylated proteinNoFD, spasticity (1/2), severe hypotoniaLeukodystrophy (1/2) WM atrophy (1/2)c.[154C > T]; [154C > T], p.[(Leu52Phe)]; [(Leu52Phe)]
c.[313A > G]; [313A > G], p.[(Arg105Gly)]; [(Arg105Gly)]
[88]10 (9F, Saudi Arabia)3–7 m/11–28 m (n = 5), alive between 10 to 34 m (n = 5)Elevated lactate and glycine levels (bl, 2/2)NAOptic atrophy and nystagmusSeizures 2/10, axial hypotonia with peripheral spasticitySevere PMR/lactate peak (1/2), glycine peak (2/2)c.[229G > A]; [229G > A], p.[(Gly77Ser)]; [(Gly77Ser)]
[89]2 (2F, Saudi Arabia)3–6 m/2 y, alive at 3 yElevated lactate (CSF), glycine, and glutamate (CSF, ur) levelsComplexes II, IV, lipoylated proteins, mtDNA depletionOptic atrophy and nystagmusPMR (2/2), spasticity, macrocephaly and syndactyly (1/2)Lesions in cerebral (PV region to U fibers 1/2) and cerebellar WM (2/2), CC, internal capsule, spinal cord (1/2)/lactate peak (2/2)c.[229G > A]; [229G > A], p.[(Gly77Ser)]; [(Gly77Ser)]
[91]1 (Italy)2 m/3 mInitially normal, elevated lactate level (CSF, later)Complexes II and IV (muscle)Nystagmus, normal fundus oculiProgressive severe hypotoniaLesions in cerebral grey and WM (U fibers, CC, spinal cord)c.[295delT]; [334A > G], p.[(Phe99Leufs*18)]; [(Ser112Gly)]
[92]1 (Iran)7 m/NANANANAHypotonia, irritability, malaise, muscle stiffnessLesions in PV WM; centrum semiovale, cerebellar peduncles/peak of lactate, increase cholinec.[355G > A]; [355G > A], p.[(Ala119Thr)]; [(Ala119Thr)]
[93]1 (Yemen/Tunisia)11 m/alive 11 yMildly elevated lactate (bl, CSF)All respiratory chain complexesNystagmusSevere hypotonia, PMR, spasticity later,Progressive lesions in PV region, genu, splenium (edema), thick CC, no spinal cord involvement/lactate peakc.[5C > A]; [413C > G],
p.[(Ala2Asp)]; [(Pro138Arg)]
Bl: blood; CC: corpus callosum; CSF: cerebrospinal fluid; d: day(s); F: families; FD: feeding difficulties; m: month(s); MRI: Magnetic resonance imaging; NA: not available; PMR: psycho-motor regression; PV: periventricular; ur: urinary; WM: white matter; y: year(s).
Table
Table 5. Reported patients with MMDS type 5.
Table 5. Reported patients with MMDS type 5.
Ref.Nb of Patients (Nb and Origin of Families)Age at Onset/Age at DeathMetabolic FindingsImpaired Mitochondrial ProteinsOphthalmic FindingsClinical FeatureBrain MRI SpectroscopyGenotype
(ISCA1:NM_030940.3)
[95]4 (2F, India)Neonate (2/4)
2–3 m (2/4)/11 m to 5 y		Elevated CPK (1/2)NANystagmus (1/4)
fundus pigmentation (1/2)		Major PMDD, SP, SE, FDPachygyria (2/4), VMG, cerebral and cerebellar WM LD/lactate peakc.[259G > A]; [259G > A], p.[(Gln87Lys)]; [(Gln87Lys)]
[97]1 (Italia)3 m/11 yHigh lactate (bl) and glycine (ur) levelsComplexes II, III, and IV, ATP synthesis, lipoylated proteinsNystagmusMild PMDD, SP, FDVacuolating LD, TCCc.[29T > G]; [29T > G], p.[(Val10Gly)]; [(Val10Gly)]
[96]1 (India)3 m/NANANANoMajor PMDD, SP, SEPachygyria (n = 2/4), VMG, cerebral and cerebellar WM LD/lactate peakc.[259G > A]; [259G > A], p.[(Gln87Lys)]; [(Gln87Lys)]
[98]1 (Egypt)20 m/alive at 7 yHigh lactate (bl) levelComplexes I, II and IV, lipoylated proteinsNoMild PMDD, SP, hemiparesisVacuolating LD, TCC, VMG/lactate peakc.[302A > G]; [302A > G], p.[(Tyr101Cys)]; [(Tyr101Cys)]
Bl: blood; CPK: creatine phospho kinase; F: families; FD: feeding difficulties; LD: leukodystrophy; m: month(s); MRI: Magnetic resonance imaging; NA: not available; PMDD: psycho-motor developmental delay; SE: seizure; SP: spasticity; TCC: thin corpus callosum; ur: urines; VMG: ventriculomegaly; WM: white matter; y: year(s).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lebigot, E.; Schiff, M.; Golinelli-Cohen, M.-P. A Review of Multiple Mitochondrial Dysfunction Syndromes, Syndromes Associated with Defective Fe-S Protein Maturation. Biomedicines 2021, 9, 989. https://doi.org/10.3390/biomedicines9080989

AMA Style

Lebigot E, Schiff M, Golinelli-Cohen M-P. A Review of Multiple Mitochondrial Dysfunction Syndromes, Syndromes Associated with Defective Fe-S Protein Maturation. Biomedicines. 2021; 9(8):989. https://doi.org/10.3390/biomedicines9080989

Chicago/Turabian Style

Lebigot, Elise, Manuel Schiff, and Marie-Pierre Golinelli-Cohen. 2021. "A Review of Multiple Mitochondrial Dysfunction Syndromes, Syndromes Associated with Defective Fe-S Protein Maturation" Biomedicines 9, no. 8: 989. https://doi.org/10.3390/biomedicines9080989

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop